The Journal of Clinical Endocrinology & Metabolism · 2022 · 31 citations · 28 references
PharmacyEndocrinologyComparative EndocrinologyMass Spectrometric AnalysisMineral MetabolismBioanalytical Method ValidationEndocrine AssessmentInterindividual VariabilityAldosterone RegulationChemiluminescence DiagnosticsFalse Negative MeasurementFalse Positive Rate AnalysisFalse Positive Rate EvaluationIntra-subject VariabilityPlasma Renin Activity
CONTEXT: Primary aldosteronism (PA) screening relies on an elevated aldosterone to renin ratio with a minimum aldosterone level, which varies from 10 to 15 ng/dL (277-415.5 pmol/L) using immunoassay. OBJECTIVE: To evaluate intra-individual coefficient of variation (CV) of aldosterone and aldosterone to direct renin concentration ratio (A/DRC) and its impact on PA screening. METHODS: A total of 671 aldosterone and DRC measurements were performed by the same chemiluminescence assays in a large cohort of 216 patients with confirmed PA and at least 2 screenings. RESULTS: The median intra-individual CV of aldosterone and A/DRC was 26.8% and 26.7%. Almost 40% of the patients had at least one aldosterone level <15 ng/dL, 19.9% had at least 2 aldosterone levels <15 ng/dL, and 16.2% had mean aldosterone levels <15 ng/dL. A lower cutoff of 10 ng/dL was associated with false negative rates for PA screening of 14.3% for a single aldosterone measurement, 4.6% for 2 aldosterone measurements, and only 2.3% for mean aldosterone levels. Considering the minimum aldosterone, true positive rate of aldosterone thresholds was 85.7% for 10 ng/dL and 61.6% for 15 ng/dL. An A/DRC >2 ng/dL/µIU/mL had a true positive rate for PA diagnosis of 94.4% and 98.4% when based on 1 or 2 assessments, respectively. CV of aldosterone and A/DRC were not affected by sex, use of interfering antihypertensive medications, PA lateralization, hypokalemia, age, and number of hormone measurements. CONCLUSION: Aldosterone concentrations had a high CV in PA patients, which results in an elevated rate of false negatives in a single screening for PA. Therefore, PA screening should be based on at least 2 screenings with concomitant aldosterone and renin measurements.
28
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams, Giuseppe Mancia, Wilko Spiering et al. · European Heart Journal · 2018 · 10.4K citations · Full text
John W. Funder, Robert M. Carey, Franco Mantero et al. · The Journal of Clinical Endocrinology & Metabolism · 2016 · 2.9K citations · Full text
Tracy Ann Williams, Jacques W.M. Lenders, Paolo Mulatero et al. · The Lancet Diabetes & Endocrinology · 2017 · 945 citations · Full text
Medicine, Endocrinology, Surgery +14